Pharos iBio Co., Ltd. (KOSDAQ:388870)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,860.00
-30.00 (-0.34%)
Last updated: Dec 10, 2025, 11:36 AM KST
16.73%
Market Cap115.09B
Revenue (ttm)n/a
Net Income (ttm)-9.82B
Shares Out12.95M
EPS (ttm)-759.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume159,796
Average Volume1,896,177
Open8,910.00
Previous Close8,890.00
Day's Range8,800.00 - 9,060.00
52-Week Range4,630.00 - 12,000.00
Beta-0.32
RSI59.05
Earnings DateNov 14, 2025

About Pharos iBio

Pharos iBio Co., Ltd. develops treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer; PHI-101-TNBC for the treatment of metastatic triple-negative breast cancer; PHI-101-RS, a radiation sensitizer; PHI-201, a K-Ras hub-protein inhibitor; PHI-301, a FAK hub-p... [Read more]

Industry Pharmaceutical Preparations
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 388870
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.